

HIV Immune Evasion Pathogenesis & Control

Exploring the complex mechanisms of HIV's immune evasion and pathogenesis while highlighting effective control strategies to combat infection.

YLM

T&C

Introduction to HIV and its Global Impact

Introduction to HIV and its Global Impact

The human immunodeficiency virus (HIV) is an enveloped retrovirus that predominantly targets CD4 T lymphocytes, leading to immunodeficiency and subsequent opportunistic infections. Since its identification in 1983, it has claimed approximately 44 million lives, with over 90 million individuals infected globally, underscoring the need for enhanced prevention strategies and therapeutic innovations, especially in light of the persistent challenge of vaccine development that has yet to yield a viable solution.



Historical Context: From SIV to HIV

Tracing the origins and epidemiological evolution of HIV, highlighting significant milestones in its transmission from non-human primates to humans.

Early 20th Century

Zoonotic spillover events from simian immunodeficiency viruses (SIV) to humans occur in Central Africa, with multiple independent transmissions leading to the emergence of HIV-1 and HIV-2.

1960s

HIV begins to spread in urban centers, particularly Kinshasa, Democratic Republic of Congo (DRC), where social and economic changes facilitate its transmission.

1981

The first cases of AIDS reported in the United States, marking the recognition of HIV as a significant public health issue.

1983

Françoise Barré-Sinoussi and Luc Montagnier identify HIV as the causative agent of AIDS, leading to significant advancements in HIV research and treatment.

1990s

Diverse HIV clades recognized, with HIV-1 group M emerging as the global pandemic strain, emphasizing the genetic diversity of the virus and its implications for treatment and vaccine development.

Present Day

Ongoing efforts to understand HIV's evolution, transmission, and pathogenesis, with a focus on developing effective vaccines and treatments to combat the pandemic.

Early 20th Century

Zoonotic spillover events from simian immunodeficiency viruses (SIV) to humans occur in Central Africa, with multiple independent transmissions leading to the emergence of HIV-1 and HIV-2.

1960s

HIV begins to spread in urban centers, particularly Kinshasa, Democratic Republic of Congo (DRC), where social and economic changes facilitate its transmission.

1981

The first cases of AIDS reported in the United States, marking the recognition of HIV as a significant public health issue.

1983

Françoise Barré-Sinoussi and Luc Montagnier identify HIV as the causative agent of AIDS, leading to significant advancements in HIV research and treatment.

1990s

Diverse HIV clades recognized, with HIV-1 group M emerging as the global pandemic strain, emphasizing the genetic diversity of the virus and its implications for treatment and vaccine development.

Present Day

Ongoing efforts to understand HIV's evolution, transmission, and pathogenesis, with a focus on developing effective vaccines and treatments to combat the pandemic.

Historical Context: From SIV to HIV

Tracing the origins and epidemiological evolution of HIV, highlighting significant milestones in its transmission from non-human primates to humans.

Early 20th Century

Zoonotic spillover events from simian immunodeficiency viruses (SIV) to humans occur in Central Africa, with multiple independent transmissions leading to the emergence of HIV-1 and HIV-2.

1960s

HIV begins to spread in urban centers, particularly Kinshasa, Democratic Republic of Congo (DRC), where social and economic changes facilitate its transmission.

1981

The first cases of AIDS reported in the United States, marking the recognition of HIV as a significant public health issue.

1983

Françoise Barré-Sinoussi and Luc Montagnier identify HIV as the causative agent of AIDS, leading to significant advancements in HIV research and treatment.

1990s

Diverse HIV clades recognized, with HIV-1 group M emerging as the global pandemic strain, emphasizing the genetic diversity of the virus and its implications for treatment and vaccine development.

Present Day

Ongoing efforts to understand HIV's evolution, transmission, and pathogenesis, with a focus on developing effective vaccines and treatments to combat the pandemic.

HIV-1 Structure: A Complex Viral Architecture

HIV-1 is characterized by a complex structure that includes a spherical shape surrounded by a lipid bilayer. This bilayer contains the envelope glycoproteins (Env) that facilitate entry into host cells. The internal structure comprises matrix proteins (MA), the capsid (CA), and nucleocapsid proteins (NC) that protect the viral RNA and associated enzymes from degradation.

HIV Genome: The Genetic Blueprint

The HIV genome is approximately 10,000 base pairs long and encodes three major structural genes: gag (encoding core proteins), pol (coding for viral enzymes), and env (responsible for the envelope proteins). The genome also includes several accessory proteins that play critical roles in modulating the host immune response and facilitating viral replication.

HIV Life Cycle: From Entry to Budding

The HIV life cycle is initiated when the viral envelope glycoprotein (Env) binds to the CD4 receptor on host cells, triggering conformational changes that allow the virus to enter the cell. Following entry, reverse transcription occurs, converting viral RNA into DNA, which is then integrated into the host genome, leading to the production of new virions.

Molecular Structure and Life Cycle of HIV

HIV-1 Structure: A Complex Viral Architecture

HIV-1 is characterized by a complex structure that includes a spherical shape surrounded by a lipid bilayer. This bilayer contains the envelope glycoproteins (Env) that facilitate entry into host cells. The internal structure comprises matrix proteins (MA), the capsid (CA), and nucleocapsid proteins (NC) that protect the viral RNA and associated enzymes from degradation.

HIV Genome: The Genetic Blueprint

The HIV genome is approximately 10,000 base pairs long and encodes three major structural genes: gag (encoding core proteins), pol (coding for viral enzymes), and env (responsible for the envelope proteins). The genome also includes several accessory proteins that play critical roles in modulating the host immune response and facilitating viral replication.

HIV Life Cycle: From Entry to Budding

The HIV life cycle is initiated when the viral envelope glycoprotein (Env) binds to the CD4 receptor on host cells, triggering conformational changes that allow the virus to enter the cell. Following entry, reverse transcription occurs, converting viral RNA into DNA, which is then integrated into the host genome, leading to the production of new virions.

Mechanisms of Immune Evasion by HIV

- Rapid viral mutation rate
- Envelope glycoprotein variability
- Latency establishment mechanisms

Pathogenesis of HIV Infection: Acute and Chronic Stages

Acute Stage of HIV Infection

During the acute stage of HIV infection, the virus undergoes rapid replication, leading to peak viremia characterized by high levels of viral RNA in the bloodstream. This phase is marked by a robust immune response that triggers a cytokine storm, a cascade of inflammatory cytokines that can contribute to systemic inflammation and damage to host tissues. Clinical manifestations may include flu-like symptoms, but many individuals remain asymptomatic, allowing for unnoticed viral transmission.





Chronic Stage of HIV Infection

In the chronic stage, the virus establishes a stable viral set point, where the replication rate and immune response reach a dynamic equilibrium. The immune system, primarily through CD8 T-cells and antibodies, attempts to control viral replication. However, this phase is characterized by a gradual depletion of CD4 T-cells, which diminishes the host's adaptive immune response and eventually leads to AIDS, marked by a CD4 T-cell count dropping below 200 cells/μL and increased susceptibility to opportunistic infections.

Clinical Consequences and Progression Phenotypes

Understanding the variability in HIV progression and its determinants.

Clinical Consequences and Progression Phenotypes

Understanding the variability in HIV progression and its determinants.

3-10y

Duration from untreated HIV infection to AIDS progression.

Clinical Consequences and Progression Phenotypes

Understanding the variability in HIV progression and its determinants.

3-10y

Duration from untreated HIV infection to AIDS progression.

<10%

Proportion of untreated patients categorized as rapid progressors or long-term non-progressors.

Clinical Consequences and Progression Phenotypes

Understanding the variability in HIV progression and its determinants.

3-10y

Duration from untreated HIV infection to AIDS progression.

200 CD4 T cells/xL

Threshold defining AIDS based on CD4 T cell counts.

<10%

Proportion of untreated patients categorized as rapid progressors or long-term non-progressors.

Clinical Consequences and Progression Phenotypes

Understanding the variability in HIV progression and its determinants.

3-10y

Duration from untreated HIV infection to AIDS progression.

200 CD4 T cells/xL

Threshold defining AIDS based on CD4 T cell counts.

<10%

Proportion of untreated patients categorized as rapid progressors or long-term non-progressors.

High viral load

Associated with faster disease progression in HIV-infected individuals.

Clinical Consequences and Progression Phenotypes

Understanding the variability in HIV progression and its determinants.

3-10y

Duration from untreated HIV infection to AIDS progression.

200 CD4 T cells/xL

Threshold defining AIDS based on CD4 T cell counts.

HLA-B*57

An HLA allele linked to elite control of HIV infection.

<10%

Proportion of untreated patients categorized as rapid progressors or long-term non-progressors.

High viral load

Associated with faster disease progression in HIV-infected individuals.

Clinical Consequences and Progression Phenotypes

Understanding the variability in HIV progression and its determinants.

3-10y

Duration from untreated HIV infection to AIDS progression.

200 CD4 T cells/xL

Threshold defining AIDS based on CD4 T cell counts.

HLA-B*57

An HLA allele linked to elite control of HIV infection.

<10%

Proportion of untreated patients categorized as rapid progressors or long-term non-progressors.

High viral load

Associated with faster disease progression in HIV-infected individuals.

CCR5x32

Genetic mutation providing resistance to HIV-1 infection.

Serological Assays for Antibody Detection

Serological assays are the cornerstone of HIV diagnosis, including enzyme-linked immunosorbent assays (ELISA) and rapid tests that detect antibodies against HIV and/or the p24 antigen. These assays can identify recent infections and have evolved to a fifth-generation format, capable of detecting both IgM and IgG antibodies alongside p24 antigen, improving early diagnosis.

Nucleic Acid Tests (NAT) for Direct Viral Detection

Nucleic Acid Tests (NAT) provide an advanced method for detecting HIV by identifying the viral RNA within a patient's blood. NAT is crucial for diagnosing acute HIV infections, where antibody tests may be negative. These tests can detect the virus within 10 days of exposure, significantly aiding in timely treatment initiation.

Point-of-Care Tests for Rapid HIV Diagnosis

Point-of-care (PoC) tests have revolutionized HIV diagnosis, allowing for rapid results directly at the site of care, often in less than 30 minutes. These tests are crucial in resource-limited settings, increasing access to HIV testing and facilitating immediate linkage to care. They can detect antibodies or the p24 antigen and are essential for outreach programs.

Diagnosis of HIV Infection: Tools and Techniques

Serological Assays for Antibody Detection

Serological assays are the cornerstone of HIV diagnosis, including enzyme-linked immunosorbent assays (ELISA) and rapid tests that detect antibodies against HIV and/or the p24 antigen. These assays can identify recent infections and have evolved to a fifth-generation format, capable of detecting both IgM and IgG antibodies alongside p24 antigen, improving early diagnosis.

Nucleic Acid Tests (NAT) for Direct Viral Detection

Nucleic Acid Tests (NAT) provide an advanced method for detecting HIV by identifying the viral RNA within a patient's blood. NAT is crucial for diagnosing acute HIV infections, where antibody tests may be negative. These tests can detect the virus within 10 days of exposure, significantly aiding in timely treatment initiation.

Point-of-Care Tests for Rapid HIV Diagnosis

Point-of-care (PoC) tests have revolutionized HIV diagnosis, allowing for rapid results directly at the site of care, often in less than 30 minutes. These tests are crucial in resource-limited settings, increasing access to HIV testing and facilitating immediate linkage to care. They can detect antibodies or the p24 antigen and are essential for outreach programs.

Antiretroviral Therapy: Achievements and Challenges

Exploring the advancements in ART while addressing the critical barriers that remain in the global fight against HIV.

1987: Introduction of AZT

The first antiretroviral drug, zidovudine (AZT), marked a significant milestone, offering initial hope for HIV-infected individuals and reducing AIDS-related mortality.

1990s: Emergence of HAART

Highly Active Antiretroviral Therapy (HAART) revolutionized HIV treatment, utilizing combination therapies to achieve viral load suppression and enhance patient outcomes.



Present: Challenges in ART Delivery

Despite advancements, challenges persist, including the emergence of drug resistance, equitable access to therapy in low-income regions, and the urgent need for a functional cure.



1987: Introduction of AZT

The first antiretroviral drug, zidovudine (AZT), marked a significant milestone, offering initial hope for HIV-infected individuals and reducing AIDS-related mortality.

1990s: Emergence of HAART

Highly Active Antiretroviral Therapy (HAART) revolutionized HIV treatment, utilizing combination therapies to achieve viral load suppression and enhance patient outcomes.



Present: Challenges in ART Delivery

Despite advancements, challenges persist, including the emergence of drug resistance, equitable access to therapy in low-income regions, and the urgent need for a functional cure.

The challenge of developing an effective HIV vaccine has persisted for over four decades. The high mutation rate of the virus, particularly in the envelope glycoprotein, presents a significant obstacle in eliciting broadly neutralizing antibodies. Current vaccine strategies have achieved limited success, as exemplified by the modest efficacy observed in the RV144 trial. Innovative approaches, such as the use of mosaic antigens, delivery systems that enhance immunogenicity, and sequential immunization strategies aimed at inducing broadly neutralizing antibodies, are critical. The focus must also include understanding the immune correlates of protection, enhancing T-cell mediated responses, and addressing the complexities of the viral reservoir. These combined efforts are essential in the quest for a successful vaccine to control and eventually eradicate HIV.

Vaccines: The Unmet Need in HIV Prevention



Geographical and Gender Disparities in HIV Infection

- Geographical HIV prevalence variations
- Impact of gender on HIV risk
- Youth vulnerability to infection
- Socioeconomic barriers affecting care
- Cultural stigmas surrounding HIV

Concluding Remarks and Future Directions

The persistent global health challenge posed by HIV necessitates a multifaceted approach that includes enhanced testing, expanded access to treatment, and the pursuit of innovative vaccine strategies. Future research must focus on understanding the virus's complex mechanisms of immune evasion and pathogenesis while also leveraging advances in immunology and virology to develop effective prophylactic and therapeutic interventions.



HIV Immune Evasion Pathogenesis & Control

Exploring the complex mechanisms of HIV's immune evasion and pathogenesis while highlighting effective control strategies to combat infection.

Take this with you. Revisit anytime.

Missed something? Want to explore further?
Scan or click below to open this presentation.
Anytime, anywhere.

View presentation